Stable Disease May Be a Valid Criterion for Continuing Hormonal Treatment in Metastatic Breast Cancer Patients

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 2
Volume 6
Issue 2

NOTTINGHAM, UK-Stable disease appears to be a clinically relevant category for judging the effectiveness of hormonal therapy in metastatic breast cancer, John Robertson, MD, said in his poster presentation of a study from the Department of Surgery, City Hospital, Nottingham.

NOTTINGHAM, UK—Stable disease appears to be a clinically relevant categoryfor judging the effectiveness of hormonal therapy in metastatic breastcancer, John Robertson, MD, said in his poster presentation of a studyfrom the Department of Surgery, City Hospital, Nottingham.

In this study of 255 breast cancer patients who received both first-and second-line hormonal therapy, patients with stable (or static) diseasefor six months had the same survival as patients who had an objective response(complete or partial remission).

"Therefore," Dr. Robertson said, "we should link thesestatic disease patients with the responders and call them nonprogressors,with all others grouped into a progressive disease category."

This finding is important, he said, because with both first- and second-linehormonal therapy, a large percentage of patients have stable disease. "Over40% of patients would be denied a benefit if physicians stopped treatmentin patients with static disease," he said.

He noted that a number of clinicians already recognize this and keeppatients on treatment while the disease is stable, "but they've neverreally been sure of the value of it. This study reassures the clinicianthat the patient should remain on treatment."

It also may be reassuring to patients to know that their cancer is beingcontrolled even though it has not gotten smaller.

Finally, he said, recognizing the importance of stable disease simplifiestreatment decision making, because progressive disease is easier to identifythan responses. "Patients can be treated purely on the premise thatyou change treatment when progression is diagnosed."

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Related Content